Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1984-3-7
|
pubmed:abstractText |
The hemodynamic effects of corwin were evaluated in 9 patients with coronary artery disease and without clinical signs of heart failure at rest, during submaximal exercise and during exercise-induced angina pectoris before and after administration of corwin. Angina pectoris was always prevented after the drug was given and the exercise intensity was increased until recurrence of angina pectoris; hemodynamic data were also recorded at this higher exercise capacity (+16%: p less than 0.001). At rest, corwin increased heart rate (from 80 to 84 beats/min) and pressure-rate product. During submaximal exercise, heart rate decreased from 105 to 96 beats/min, and pressure-rate product and ST-segment depression also decreased after corwin. The prevention of angina pectoris in all patients was accompanied by a lower heart rate (from 132 to 117 beats/min), pressure-rate product and ST-segment depression. At rest and during exercise, the cardiac output was unchanged and the pulmonary capillary wedge pressure was slightly decreased after corwin (from 12.5 to 10 mm Hg; p less than 0.001). At the 16% greater exercise capacity after corwin, angina pectoris recurred at the same values of cardiac output, pulmonary wedge pressure and ST-segment depression; maximal heart rate decreased from 132 to 124 beats/min, and the pressure-rate product was lower. Thus, corwin is an active antianginal drug. Its effects are likely due to a decrease in pressure-rate product and myocardial oxygen requirements during exercise. In contrast to beta-antagonists devoid of partial agonist activity, corwin does not depress left ventricular function either at rest or during exercise.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
439-43
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:6141726-Adrenergic beta-Agonists,
pubmed-meshheading:6141726-Angina Pectoris,
pubmed-meshheading:6141726-Cardiac Output,
pubmed-meshheading:6141726-Coronary Disease,
pubmed-meshheading:6141726-Heart Rate,
pubmed-meshheading:6141726-Humans,
pubmed-meshheading:6141726-Male,
pubmed-meshheading:6141726-Middle Aged,
pubmed-meshheading:6141726-Myocardial Contraction,
pubmed-meshheading:6141726-Physical Exertion,
pubmed-meshheading:6141726-Propanolamines,
pubmed-meshheading:6141726-Pulmonary Wedge Pressure,
pubmed-meshheading:6141726-Stimulation, Chemical,
pubmed-meshheading:6141726-Xamoterol
|
pubmed:year |
1984
|
pubmed:articleTitle |
Antianginal effects of corwin, a new beta-adrenoceptor partial agonist.
|
pubmed:publicationType |
Journal Article
|